Browsing: immunotherapy

Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for many cancers, producing durable responses in diseases that were once associated with poor outcomes. Yet only a subset of patients achieves long-term benefit, highlighting the need to better understand the host-related factors that influence immunotherapy efficacy

Physiological host factors, such as the gut microbiome and obesity, independently influence anti-tumour immunity and responses to immune checkpoint inhibitors (ICIs)1, with high body mass index (BMI) having an unexpected link with greater ICI efficacy2,3,4,5,6. However, how these factors interact across diverse dietary contexts remains unclear. Here, using 12 mouse diet models that reflect a spectrum…